NASDAQ:ADMP Adamis Pharmaceuticals (ADMP) Stock Forecast, Price & News $2.04 -0.12 (-5.56%) (As of 05:34 PM ET) Add Compare Share Share Today's Range$2.04▼$2.1750-Day Range$2.07▼$223.3052-Week Range$1.91▼$38.18Volume50,721 shsAverage Volume39,673 shsMarket Capitalization$5.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Adamis Pharmaceuticals (NASDAQ:ADMP) StockAdamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets. It offers the SYMJEPI Injection for the emergency treatment of allergic reactions. The company was founded in June 2006 and is headquartered in San Diego, CA.Read More Receive ADMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adamis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADMP Stock News HeadlinesJune 4, 2023 | fool.comAdamis Pharmaceuticals (NASDAQ: ADMP)May 31, 2023 | benzinga.comAdamis Pharmaceuticals CEO Awarded $210K Worth of Stock OptionsJune 8, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 31, 2023 | benzinga.comBoard Member at Adamis Pharmaceuticals Acquires Company Stock Options Worth 25,720 SharesMay 31, 2023 | americanbankingnews.comAdamis Pharmaceuticals (NASDAQ:ADMP) Earns Sell Rating from Analysts at StockNews.comMay 30, 2023 | americanbankingnews.comAdamis Pharmaceuticals (NASDAQ:ADMP) Receives New Coverage from Analysts at StockNews.comMay 26, 2023 | americanbankingnews.comAdamis Pharmaceuticals Co. (NASDAQ:ADMP) Sees Significant Drop in Short InterestMay 26, 2023 | finanznachrichten.deAdamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Announces Closing of the Merger with DMK PharmaceuticalsJune 8, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 25, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces Closing of the Merger with DMK PharmaceuticalsMay 24, 2023 | americanbankingnews.comAdamis Pharmaceuticals (NASDAQ:ADMP) Hits New 52-Week Low at $3.10May 21, 2023 | seekingalpha.comAdamis Pharma slips 19% on plans for reverse stock slipMay 19, 2023 | finanznachrichten.deAdamis Pharmaceuticals Corporation: Adamis Pharmaceuticals Announces Reverse Stock SplitMay 19, 2023 | finance.yahoo.comAdamis Pharmaceuticals Announces Reverse Stock SplitMay 16, 2023 | finance.yahoo.comQ1 2023 Adamis Pharmaceuticals Corp Earnings CallMay 15, 2023 | finance.yahoo.comAdamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 15, 2023 | americanbankingnews.comAdamis Pharmaceuticals (NASDAQ:ADMP) Coverage Initiated at StockNews.comMay 13, 2023 | americanbankingnews.comAdamis Pharmaceuticals Co. (NASDAQ:ADMP) Short Interest UpdateMay 8, 2023 | finance.yahoo.comAdamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate UpdateMay 7, 2023 | marketwatch.com8-K: Adamis Pharmaceuticals CorpMay 7, 2023 | americanbankingnews.comAdamis Pharmaceuticals (NASDAQ:ADMP) Research Coverage Started at StockNews.comApril 28, 2023 | americanbankingnews.comAdamis Pharmaceuticals (NASDAQ:ADMP) Now Covered by Analysts at StockNews.comApril 21, 2023 | americanbankingnews.comAdamis Pharmaceuticals (NASDAQ:ADMP) Earns Hold Rating from Analysts at StockNews.comApril 5, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Adamis Pharmaceuticals (NASDAQ:ADMP)April 1, 2023 | americanbankingnews.comAdamis Pharmaceuticals Co. (NASDAQ:ADMP) Sees Large Growth in Short InterestMarch 21, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Adamis Pharmaceuticals (NASDAQ:ADMP)March 19, 2023 | finance.yahoo.comAdamis Pharmaceuticals Corporation (NASDAQ:ADMP) Q4 2022 Earnings Call TranscriptSee More Headlines ADMP Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADMP Company Calendar Last Earnings3/31/2022Today6/08/2023Next Earnings (Estimated)8/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADMP CUSIPN/A CIK887247 Webwww.adamispharmaceuticals.com Phone(858) 997-2400FaxN/AEmployees116Year Founded2006Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-26,480,000.00 Net Margins-495.95% Pretax Margin-495.08% Return on Equity-420.53% Return on Assets-201.34% Debt Debt-to-Equity RatioN/A Current Ratio0.58 Quick Ratio0.53 Sales & Book Value Annual Sales$4.76 million Price / Sales1.08 Cash FlowN/A Price / Cash FlowN/A Book Value($0.38) per share Price / Book-5.45Miscellaneous Outstanding Shares2,490,000Free Float2,456,000Market Cap$5.15 million OptionableOptionable Beta1.22 Social Links Key ExecutivesEbrahim VersiChairman & Chief Executive OfficerDavid J. MarguglioPresident, Chief Operating Officer & SecretaryDavid C. BenedictoChief Financial OfficerThomas H. MollVice President-ResearchRobert H. UhlInvestor Relations ContactKey CompetitorsKintara TherapeuticsNASDAQ:KTRAQualigen TherapeuticsNASDAQ:QLGNBiophytisNASDAQ:BPTSTimber PharmaceuticalsNYSE:TMBRArtelo BiosciencesNASDAQ:ARTLView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 14,500,000 shares on 5/16/2023Ownership: 8.710%HighTower Advisors LLCSold 840 shares on 5/12/2023Ownership: 0.000%Simplex Trading LLCBought 500 shares on 4/27/2023Ownership: 0.000%View All Institutional Transactions ADMP Stock - Frequently Asked Questions How have ADMP shares performed in 2023? Adamis Pharmaceuticals' stock was trading at $11.8510 at the beginning of 2023. Since then, ADMP stock has decreased by 81.8% and is now trading at $2.16. View the best growth stocks for 2023 here. Are investors shorting Adamis Pharmaceuticals? Adamis Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 17,600 shares, a decrease of 97.8% from the April 30th total of 799,900 shares. Based on an average daily trading volume, of 33,700 shares, the short-interest ratio is presently 0.5 days. View Adamis Pharmaceuticals' Short Interest. When is Adamis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023. View our ADMP earnings forecast. How were Adamis Pharmaceuticals' earnings last quarter? Adamis Pharmaceuticals Co. (NASDAQ:ADMP) issued its quarterly earnings results on Thursday, March, 31st. The specialty pharmaceutical company reported ($4.20) EPS for the quarter, missing the consensus estimate of ($2.80) by $1.40. Adamis Pharmaceuticals had a negative net margin of 495.95% and a negative trailing twelve-month return on equity of 420.53%. During the same quarter in the previous year, the firm earned ($11.20) EPS. When did Adamis Pharmaceuticals' stock split? Adamis Pharmaceuticals shares reverse split on the morning of Monday, May 22nd 2023. The 1-70 reverse split was announced on Monday, May 22nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Adamis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Trevena (TRVN), Amarin (AMRN), Sorrento Therapeutics (SRNE), Verastem (VSTM), Dynavax Technologies (DVAX), Novavax (NVAX), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Agile Therapeutics (AGRX) and OPKO Health (OPK). What is Adamis Pharmaceuticals' stock symbol? Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP." Who are Adamis Pharmaceuticals' major shareholders? Adamis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (8.71%), Simplex Trading LLC (0.00%) and HighTower Advisors LLC (0.00%). Insiders that own company stock include David C Benedicto, David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert O Hopkins and Ronald B Moss. View institutional ownership trends. How do I buy shares of Adamis Pharmaceuticals? Shares of ADMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Adamis Pharmaceuticals' stock price today? One share of ADMP stock can currently be purchased for approximately $2.16. How much money does Adamis Pharmaceuticals make? Adamis Pharmaceuticals (NASDAQ:ADMP) has a market capitalization of $5.38 million and generates $4.76 million in revenue each year. How many employees does Adamis Pharmaceuticals have? The company employs 116 workers across the globe. How can I contact Adamis Pharmaceuticals? Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.adamispharmaceuticals.com. The specialty pharmaceutical company can be reached via phone at (858) 997-2400 or via email at mflather@adamispharma.com. This page (NASDAQ:ADMP) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adamis Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.